一种新番荔枝内酯单体atemoyacin-B克服肿瘤多药抗药性(英文)

被引：2

作者：

符立梧

潘启超

梁永钜

黄红兵

机构：

[1] 中山医科大学肿瘤防治中心

[2] 中山医科大学肿瘤防治中心广州中国

[3] 广州中国

来源：

ActaPharmacologicaSinica | 1999年 / 05期

关键词：

番荔枝内酯; bullatacin; atemoyacin-B; 多种抗药性; Furd-2; 多柔比星; 长春新碱; 细胞凋亡; 培养的肿瘤细胞; 植物性抗肿瘤药;

D O I：

暂无

中图分类号：

R73-36 [治疗实验];

学科分类号：

100214 ;

摘要：

目的:探讨atemoyacin-B（Ate）克服肿瘤多药抗药性（MDR）作用及其机制,方法:Bullatacin（Bul）为阳性对照物,细胞毒测定以MTT法;P-gp功能测定以Fura 2-AM法;细胞内药物积累测定以荧光分光光度计法;细胞凋亡测定以流式细胞仪法,结果:Ate对MCF-7/Dox,MCF-7,KBvzoo和KB细胞的IC50分别为122,120,1.34,1.27 nmol·L-1,Ate显著增加MDR细胞内Fura-2及多柔比星（Dox）的积累,但不增加相应敏感细胞的细胞内Fura-2及Dox的积累,Ate也能诱导MDR细胞凋亡.结论:MDR细胞对Ate同样敏感,不受抗药性影响,其机制与降低P-gp功能及增加细胞内药物积累有关。

引用

页码：53 / 57

页数：5

共 10 条

[1]

Leukemia[P]. 英国专利:GB0221802D0,2002-10-30

[2]

Atemoyacin B: a new bis-tetrahydrofuranyl annonaceous acetogenin from Annona atemoya H. Chen WS,Yao ZJ,Zhang YB,Xu YZ,Wu YL. Chinese Journal of Chemistry . 1995

[3]

Anti cancer drugs[P]. 英国专利:GB9618634D0,1996-10-16

[4]

Modulatory effects of tamoxifen and recombinant human α-interferon on doxombicin resistance. Kang Y,Perry RR. Cancer Research . 1993

[5]

A new method for the screening of the drug with multidrug resistance reversing activity by Fura 2-AM. Fu LW,Pan QC. Chinese Pharmaceutical Journal . 1995

[6]

The annonaceous acetogenin bullatacin is cytotoxic against multidmg-resistant human mammary adenocarcinoma cells. Oberlies NH,Croy VL,Harrison ML,McLaughlin JL. Cancer Letters . 1997

[7]

Evaluation of a tetrazoliurn-based semiautomated colorimetric assay: assessment of radiosensitivity. Carmichael J,DeGraff WG,Gazadar AF,Minna JD,Mitchell JB. Cancer Research . 1987

[8]

The properties of compounds with reversing tumor multidrug resistance. Fu LW,Pan QC. Chinese Journal of Cancer Research . 1996

[9]

Tumor multidrug resistance reversed by various Chinese herb principles. Pan QC,Tian H. Chinese Science Bulletin . 1995

[10]

Mode of action of bullatacin, a potent antitumor acetogenin: inhibition of NADH oxidase activity of HeLa and HL-60, but not liver, plasma membranes. Morre DJ,de Cabo R,Farley C,Oberlies NH,McLaughlin JL. Life Sciences . 1995

← 1 →